Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0V4RO
|
||||
Former ID |
DNC004990
|
||||
Drug Name |
3-(3-Pyridin-2-yl-pyrazol-1-yl)-benzonitrile
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C15H10N4
|
||||
Canonical SMILES |
C1=CC=NC(=C1)C2=NN(C=C2)C3=CC=CC(=C3)C#N
|
||||
InChI |
1S/C15H10N4/c16-11-12-4-3-5-13(10-12)19-9-7-15(18-19)14-6-1-2-8-17-14/h1-10H
|
||||
InChIKey |
FUXJRPCONXOULZ-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Metabotropic glutamate receptor 5 | Target Info | Inhibitor | [1] | |
KEGG Pathway | Calcium signaling pathway | ||||
Neuroactive ligand-receptor interaction | |||||
Gap junction | |||||
Long-term potentiation | |||||
Retrograde endocannabinoid signaling | |||||
Glutamatergic synapse | |||||
Huntington's disease | |||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
Metabotropic glutamate receptor group III pathway | |||||
Metabotropic glutamate receptor group I pathway | |||||
Endogenous cannabinoid signaling | |||||
Reactome | G alpha (q) signalling events | ||||
Class C/3 (Metabotropic glutamate/pheromone receptors) | |||||
WikiPathways | Hypothetical Network for Drug Addiction | ||||
GPCRs, Class C Metabotropic glutamate, pheromone | |||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | J Med Chem. 2004 Sep 9;47(19):4645-8.Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.